EMA Withdrawn: ChondroCelect (characterised viable autologous cartilage cells expanded ex vivo expressing specific marker proteins) — TiGenix N.V.

View source ↗

Summary

The EMA has withdrawn ChondroCelect, a therapy using autologous cartilage cells expanded ex vivo, from the market.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cartilage Diseases

Drugs mentioned

• ChondroCelect (autologous chondrocyte therapy)

Snippet

Status: Withdrawn. Therapeutic area: Cartilage Diseases. MAH: TiGenix N.V.. Decision date: 29/07/2016